Top

Published in:

Open Access 01-12-2021 | Pancreatic Cancer | Research

Comprehensive analysis of the transcriptional expressions and prognostic value of S100A family in pancreatic ductal adenocarcinoma

Authors: Hong-Bin Li, Jian-Li Wang, Xiao-Dong Jin, Lei Zhao, Hui-Li Ye, Yan-bei Kuang, Yong Ma, Xiang-Yan Jiang, Ze-Yuan Yu

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Pancreatic ductal adenocarcinoma (PDAC) remains a treatment-refractory malignancy with poor prognosis. It is urgent to identify novel and valid biomarkers to predict the progress and prognosis of PDAC. The S100A family have been identified as being involved in cell proliferation, migration and differentiation progression of various cancer types. However, the expression patterns and prognostic values of S100As in PDAC remain to be analyzed.

Methods

We investigated the transcriptional expressions, methylation level and prognostic value of S100As in PDAC patients from the Oncomine, GEPIA2, Linkedomics and cBioPortal databases. Real-time PCR was used to detect the expressions of S100A2/4/6/10/14/16 in four pancreatic cancer cell lines and pancreatic cancer tissues from PDAC patients undergoing surgery. To verify the results further, immunohistochemistry was used to measure the expression of S100A2/4/6/10/14/16 in 43 PDAC patients’ tissue samples. The drug relations of S100As were analyzed by using the Drugbank database.

Results

The results suggested that, the expression levels of S100A2/4/6/10/14/16 were elevated to PDAC tissues than in normal pancreatic tissues, and the promoter methylation levels of S100A S100A2/4/6/10/14/16 in PDAC (n = 10) were lower compared with normal tissue (n = 184) (P < 0.05). In addition, their expressions were negatively correlated with PDAC patient survival.

Conclusions

Taken together, these results suggest that S100A2/4/6/10/14/16 might be served as prognostic biomarkers for survivals of PDAC patients.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Wang Z, Hausmann S, Lyu R, Li TM, Lofgren SM, Flores NM, et al. SETD5-coordinated chromatin reprogramming regulates adaptive resistance to targeted pancreatic cancer therapy. Cancer Cell. 2020;37(6):834–49. https://doi.org/10.1016/j.ccell.2020.04.014.CrossRefPubMedPubMedCentral

Liermann J, Shinoto M, Syed M, Debus J, Herfarth K, Naumann P. Carbon ion radiotherapy in pancreatic cancer: a review of clinical data. Radiother Oncol. 2020;147:145–50. https://doi.org/10.1016/j.radonc.2020.05.012.CrossRefPubMed

Marchi S, Vitto VAM, Danese A, Wieckowski MR, Giorgi C, Pinton P. Mitochondrial calcium uniporter complex modulation in cancerogenesis. Cell Cycle. 2019;18(10):1068–83. https://doi.org/10.1080/15384101.2019.1612698.CrossRefPubMedPubMedCentral

Cmoch A, Groves P, Palczewska M, Pikuła S. S100A proteins in propagation of a calcium signal in norm and pathology. Postepy Biochem. 2012;58(4):429–36.PubMed

Tong LLW, Lim RR, Chaurasia SS. S100A proteins as molecular targets in the ocular surface inflammatory diseases. Ocul Surf. 2014;12(1):23–31. https://doi.org/10.1016/j.jtos.2013.10.001.CrossRefPubMed

El-Rifai W, Moskaluk CA, Abdrabbo MK, et al. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res. 2002;62(23):6823–6.PubMed

Gupta S, Hussain T, MacLennan GT, et al. Differential expression of S100A2 and S100A4 during progression of human prostate adenocarcinoma. J Clin Oncol. 2003;21(1):106–12. https://doi.org/10.1200/JCO.2003.03.024.CrossRefPubMed

Wang G, Wang X, Wang S, Song H, Sun H, Yuan W, et al. Colorectal cancer progression correlates with upregulation of S100A11 expression in tumor tissues. Int J Color Dis. 2008;23(7):675–82. https://doi.org/10.1007/s00384-008-0464-6.CrossRef

10.

Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–58. https://doi.org/10.1016/j.neo.2017.05.002.CrossRefPubMedPubMedCentral

11.

Koch A, Jeschke J, Van Criekinge W, et al. MEXPRESS update 2019. Nucleic Acids Res. 2019;47(W1):W561–5. https://doi.org/10.1093/nar/gkz445.CrossRefPubMedPubMedCentral

12.

Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074–82. https://doi.org/10.1093/nar/gkx1037.CrossRefPubMed

13.

Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523. https://doi.org/10.1038/s41467-019-09234-6.CrossRefPubMedPubMedCentral

14.

Yu ZY, Jiang XY, Zhao RR, Qin JJ, Luo CJ, Ren YX, et al. Effect of KIF22 on promoting proliferation and migration of gastric cancer cells via MAPK-ERK pathways. Chin Med J. 2020;133(8):919–28. https://doi.org/10.1097/CM9.0000000000000742.CrossRefPubMedPubMedCentral

15.

Okada M, Tokumitsu H, Kubota Y, Kobayashi R. Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002;292(4):1023–30. https://doi.org/10.1006/bbrc.2002.6761.CrossRefPubMed

16.

Koch M, Bhattacharya S, Kehl T, Gimona M, Vašák M, Chazin W, et al. Implications on zinc binding to S100A2. Biochim Biophys Acta. 1773;2007(3):457–70. https://doi.org/10.1016/j.bbamcr.2006.12.006.CrossRef

17.

Haase-Kohn C, Wolf S, Lenk J, Pietzsch J. Copper-mediated cross-linking of S100A4, but not of S100A2, results in proinflammatory effects in melanoma cells. Biochem Biophys Res Commun. 2011;413(3):494–8. https://doi.org/10.1016/j.bbrc.2011.08.132.CrossRefPubMed

18.

Malashkevich VN, Dulyaninova NG, Ramagopal UA, Liriano MA, Varney KM, Knight D, et al. Phenothiazines inhibit S100A4 function by inducing protein oligomerization. Proc Natl Acad Sci U S A. 2010;107(19):8605–10. https://doi.org/10.1073/pnas.0913660107.CrossRefPubMedPubMedCentral

19.

Jin X, Fang R, Fan P, Zeng L, Zhang B, Lu X, et al. PES1 promotes BET inhibitors resistance and cells proliferation through increasing c-Myc expression in pancreatic cancer. J Exp Clin Cancer Res. 2019;38(1):463. https://doi.org/10.1186/s13046-019-1466-7.CrossRefPubMedPubMedCentral

20.

Goehrig D, Nigri J, Samain R, Wu Z, Cappello P, Gabiane G, et al. Stromal protein βig-h3 reprogrammes tumour microenvironment in pancreatic cancer. Gut. 2019;68(4):693–707. https://doi.org/10.1136/gutjnl-2018-317570.CrossRefPubMed

21.

Collaborators GPC. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2019;4:934–47.CrossRef

22.

Hua X, Zhang H, Jia J, Chen S, Sun Y, Zhu X. Roles of S100 family members in drug resistance in tumors: status and prospects. Biomed Pharmacother. 2020;127:110156. https://doi.org/10.1016/j.biopha.2020.110156.CrossRefPubMed

23.

Gonzalez LL, Garrie K, Turner MD. Role of S100 proteins in health and disease. Biochim Biophys Acta, Mol Cell Res. 1867;2020(6):118677. https://doi.org/10.1016/j.bbamcr.2020.118677.CrossRef

24.

Fei F, Liu K, Li C, du J, Wei Z, Li B, et al. Molecular mechanisms by which S100A4 regulates the migration and invasion of PGCCs with their daughter cells in human colorectal Cancer. Front Oncol. 2020;10:182. https://doi.org/10.3389/fonc.2020.00182.CrossRefPubMedPubMedCentral

25.

Li Y, Wang J, Song K, Liu S, Zhang H, Wang F, et al. S100A4 promotes hepatocellular carcinogenesis by intensifying fibrosis-associated cancer cell stemness. Oncoimmunology. 2020;9(1):1725355. https://doi.org/10.1080/2162402X.2020.1725355.CrossRefPubMedPubMedCentral

26.

Xu X, Su B, Xie C, Wei S, Zhou Y, Liu H, et al. Sonic hedgehog-Gli1 signaling pathway regulates the epithelial mesenchymal transition (EMT) by mediating a new target gene, S100A4, in pancreatic cancer cells. PLoS One. 2014;9(7):e96441. https://doi.org/10.1371/journal.pone.0096441.CrossRefPubMedPubMedCentral

27.

Sabates-Bellver J, Van der Flier LG, de Palo M, et al. Transcriptome profile of human colorectal adenomas. Mol Cancer Res. 2007;5(12):1263–75. https://doi.org/10.1158/1541-7786.MCR-07-0267.CrossRefPubMed

28.

Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001;98(24):13790–5. https://doi.org/10.1073/pnas.191502998.CrossRefPubMedPubMedCentral

29.

Bachet JB, Maréchal R, Demetter P, Bonnetain F, Cros J, Svrcek M, et al. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma. Eur J Cancer. 2013;49(12):2643–53. https://doi.org/10.1016/j.ejca.2013.04.017.CrossRefPubMed

30.

Filipek A, Leśniak W. S100A6 and its brain ligands in neurodegenerative disorders. Int J Mol Sci. 2020;21(11). https://doi.org/10.3390/ijms21113979.

31.

Arai K, Iwasaki T, Sonoda A, Endo A. Membranous overexpression of S100A10 is associated with a high-grade cellular status of breast carcinoma. Med Mol Morphol. 2020;53(2):104–14. https://doi.org/10.1007/s00795-019-00236-3.CrossRefPubMed

32.

Hu L, Kong F, Pan Y. Prognostic and clinicopathological significance of S100A14 expression in cancer patients: a meta-analysis. Med Sci Sports Exerc. 2019;98(28):e16356. https://doi.org/10.1097/MD.0000000000016356.CrossRef

33.

Hatoum D, Yagoub D, Ahadi A, Nassif NT, McGowan EM. Annexin/S100A protein family regulation through p14ARF-p53 activation: a role in cell survival and predicting treatment outcomes in breast cancer. PLoS One. 2017;12(1):e0169925. https://doi.org/10.1371/journal.pone.0169925.CrossRefPubMedPubMedCentral

Title: Comprehensive analysis of the transcriptional expressions and prognostic value of S100A family in pancreatic ductal adenocarcinoma
Authors: Hong-Bin Li
Jian-Li Wang
Xiao-Dong Jin
Lei Zhao
Hui-Li Ye
Yan-bei Kuang
Yong Ma
Xiang-Yan Jiang
Ze-Yuan Yu
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Pancreatic Cancer
Pancreatic Cancer
Biomarkers
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08769-6

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Extracellular vesicles shed from gastric cancer mediate protumor macrophage differentiation

Lung cancer incidence differences in migrant men in Belgium, 2004–2013: histology-specific analyses

Definitive carbon ion radiotherapy for tracheobronchial adenoid cystic carcinoma: a preliminary report

Factors to improve distress and fatigue in Cancer survivorship; further understanding through text analysis of interviews by machine learning

Reconstructive outcome analysis of the impact of neoadjuvant chemotherapy on immediate breast reconstruction: a retrospective cross-sectional study